The All Ordinaries Index (ASX: XAO) is up 0.6% today, with ASX All Ords stock Orthocell Ltd (ASX: OCC) leaping ahead of those gains.
Shares in the regenerative medicine company closed yesterday trading for $1.435. In early morning trade on Thursday, shares are changing hands for $1.530 apiece, up 6.6%.
This sees the Orthocell share price up a whopping 273.2% since this time last year.
Here's what's stoking investor interest today.
ASX All Ords stock leaps on record results
Investors are bidding up the Orthocell share price following the release of the company's quarterly results for the three months to 30 September.
Among the highlights, the ASX All Ords stock achieved record revenue of $3 million for the quarter. Orthocell said this was driven by increasing market penetration of its nerve repair product Remplir in both Australia and Singapore.
The September revenue figure is up 9.1% from the company's previous quarterly record of $2.7 million, achieved in the June 2025 quarter.
And in a promising growth sign, this marks the sixth consecutive quarter of record revenue for Orthocell.
The ASX All Ords stock noted that the record revenue results are yet to include "material revenue" from its Remplir sales in the United States. The company expects US sales revenues to build during the December 2025 quarter and grow into the second half of the 2026 financial year (FY 2026).
Canada also presents a potential growth market, with Orthocell recently appointing its first Canadian distributor. The company is targeting initial sales from this region in the December quarter.
What did management say?
Commenting on the quarterly results boosting the ASX All Ords stock today, Orthocell CEO Paul Anderson said, "The record revenue result for the September quarter is a particularly pleasing result, given it has largely been achieved from our existing markets in Australia and Singapore."
He noted that the results are "a tangible confirmation that surgeons are growing increasingly comfortable using Remplir in nerve repair procedures".
Anderson added:
Our US Remplir rollout remains on target with early surgical cases having been successfully undertaken during the quarter. As expected, these cases represented a modest financial contribution in the September quarter, but we see significant upside in our revenue growth potential as US momentum builds, and Canada comes online.
This is the market entry plan we followed in Australia and Singapore, and we hope to replicate it on a far larger scale in the US.
The ASX All Ords stock ended the quarter with $27 million in cash and no debt.
